Cardium Therapeutics Inc., a wholly-owned subsidiary of Aries Ventures Inc., has announced the addition of Jennifer A. Spinella as Vice President - Regulatory Affairs.
Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics said, "We are pleased to welcome Jennifer to Cardium Therapeutics. Jennifer's significant experience in pharmaceutical product development will assist us with the regulatory approval process relating to the commercial development of our lead product, Generx, a DNA-based angiogenic therapeutic."
Ms. Spinella was formerly Director of Regulatory Affairs at Biogen Idec Inc. and was responsible for the regulatory strategy and recent supplemental Biologics License Application (sBLA) for Rituxan® in Rheumatoid Arthritis.
Before joining Biogen Idec in 2003, she was Director of Regulatory Affairs at Idun Pharmaceuticals Inc. and held various regulatory positions at Elan Pharmaceuticals Inc., Chugai Biopharmaceuticals Inc., Dura Pharmaceuticals Inc. and Gensia Pharmaceuticals Inc.
Ms. Spinella earned her B.S. in Medical Technology from the University of Nebraska College of Medicine, Omaha, Nebraska.